Results 31 to 40 of about 1,815 (184)

Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis [PDF]

, 2017
The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure hospitalization in the EMPA-REG OUTCOMES trial has raised the possibility of using these agents to treat established heart failure.
De Vecchis, Ferrannini, Fitchett, Francis, Greenberg, Hammon, Heise, Heise, Hirose, Lindner, Neal, Peacock, Rabe, Schmieder, Schneider, Schrier, Schrier, Shimizu, Titze, Titze, Titze, Weinfeld, Zinman   +22 more
core   +1 more source

Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes

Biomedicines, 2021
Background: Decreased insulin clearance could be a relatively upstream abnormality in obesity, metabolic syndrome, and nonalcoholic fatty liver disease. Previous studies have shown that sodium-glucose cotransporter 2 inhibitor (SGLT2i) increases insulin ...
Motonori Sato, Yoshifumi Tamura, Hideyoshi Kaga, Nozomu Yamasaki, Mai Kiya, Satoshi Kadowaki, Daisuke Sugimoto, Takashi Funayama, Yuki Someya, Saori Kakehi, Shuko Nojiri, Hiroaki Satoh, Ryuzo Kawamori, Hirotaka Watada   +13 more
doaj   +1 more source

SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus [PDF]

, 2016
OBJECTIVE: To review the chemistry, pharmacology, pharmacodynamics, pharmacokinetics, clinical efficacy, tolerability, dosing, drug interactions, and administration of canagliflozin, dapagliflozin, and empagliflozin, and comparing the benefit and risk ...
Ahmed-Sarwar, Nabila, Nathan, Kobi T, Werner, Paul M   +2 more
core   +2 more sources

Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study

Cardiovascular Diabetology, 2020
Background This study aimed to investigate the preventive effects of tofogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease ...
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, the UTOPIA study investigators   +26 more
doaj   +1 more source

Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus [PDF]

, 2016
The benefit or risk of sodium glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus has not been established.
Cui, Wei, Fang, Zhenwei, Song, Yiqing, Tang, Huilin, Wang, Tiansheng, Zhai, Suodi   +5 more
core   +2 more sources

A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy-A Systematic Review and Meta-Analysis [PDF]

, 2023
The increase in life expectancy without a decrease in the years lived without disability leads to the rise of the population aged over 65 years prone to polypharmacy.
Banach, Maciej, Bica, Ioana-Cristina, Busnatu, Stefan, Janez, Andrej, Muzurović, Emir, Pantea Stoian, Anca, Rizvi, Ali Abbas, Rizzo, Manfredi, Salmen, Teodor, Serafinceanu, Cristian, Serbanoiu, Liviu-Ionut   +10 more
core   +1 more source

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis [PDF]

, 2016
Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for the treatment of diabetes. We aimed at describing the maximal benefits and risks associated with SGLT2-i for patients with type 2 diabetes.Systematic review and meta-analysis.
A Berhan, A Lewin, A Liakos, A Patel, AK Singh, B Bode, B Bode, B Neal, B Zinman, C Mathieu, C Sonesson, C Triplitt, Cathy Bennett, CJ Bailey, CJ Bailey, CJ Bailey, CS Kovacs, CS Kovacs, D Moher, D Vasilakou, DS Shyangdan, E Ferrannini, E Ferrannini, E Ferrannini, E Ferrannini, E Ferrannini, F Zaccardi, Filip K. Knop, FJ Lavalle-Gonzalez, G Guyatt, G Musso, G Schernthaner, H Liu, H Storgaard, H Storgaard, Heidi Storgaard, HJ Lambers Heerspink, HU Haering, HU Haring, HU Haring, IM Stratton, J Bolinder, J Bolinder, J Rosenstock, J Rosenstock, J Rosenstock, J Rosenstock, J Rosenstock, J Rosenstock, J Yoon, JF List, JH Wu, JP Wilding, JP Wilding, JP Wilding, JP Wilding, K Damman, K Kaku, K Kaku, K Stenlof, K Stenlof, K Strojek, K Strojek, L Ji, L Merker, LA Leiter, LA Leiter, LA Leiter, Lise L. Gluud, M Laakso, M Ridderstrale, M Ridderstråle, M Roden, M Sarnak, MA Nauck, MA Nauck, Magnus F. Grøndahl, MH Ahmed, Mikkel B. Christensen, N Inagaki, Noel Christopher Barengo, O Ljunggren, P Gaede, P Jose, RA DeFronzo, RR Henry, RR Holman, S Del Prato, S Goring, S Kalra, S Matthaei, S Matthaei, S Ross, SA Jabbour, SE Inzucchi, SE Kahn, T Forst, T Kadowaki, Tina Vilsbøll, W Duckworth, WL Baker, WT Cefalu, WT Cefalu, Y Yilmaz   +103 more
core   +7 more sources

Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall—a sub-analysis of the UTOPIA trial

Cardiovascular Diabetology, 2022
Background Since sodium-glucose cotransporter 2 (SGLT2) inhibitors have a pleiotropic antiatherogenic effect, they are expected to attenuate the progression of atherosclerosis.
Naoto Katakami, Tomoya Mita, Norikazu Maeda, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, The UTOPIA Study Investigators   +6 more
doaj   +1 more source

The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis–associated liver tumors in a novel murine model [PDF]

, 2021
doctoral ...
Yoshioka, Naoki, 吉岡, 直輝
core  

Tofogliflozin decreases body fat mass and improves peripheral insulin resistance [PDF]

Diabetes, Obesity and Metabolism, 2018
The impact of tofogliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM) was investigated using the hyperinsulinaemic‐euglycaemic clamp method in a single‐arm, open‐label study. The following variables were compared between before and after tofogliflozin
Ren Matsuba, Ikuro Matsuba, Mototsugu Shimokawa, Yoshio Nagai, Yasushi Tanaka   +4 more
openaire   +2 more sources